Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXLAPF)

Drug Name

UCB-11056 Drug Info

Synonyms

127390-77-6; Ucb-11056; Ucb 11056; 2-(4-morpholino-6-propyl-1,3,5-triazin-2-yl)aminoethanol; UNII-MU6BC50P47; MU6BC50P47; 2-((4-Morpholino-6-propyl-1,3,5-triazin-2-yl)amino)ethanol; 2-((4-(4-Morpholinyl)-6-propyl-1,3,5-triazin-2-yl)amino)ethanol; Ethanol,2-[[4-(4-morpholinyl)-6-propyl-1,3,5-triazin-2-yl]amino]-; Ethanol, 2-((4-(4-morpholinyl)-6-propyl-1,3,5-triazin-2-yl)amino)-; NERMEVBNTXXDNG-UHFFFAOYSA-N; ACMC-20msf9; AC1L2Y9Y; SCHEMBL3365592; CTK4B5589; DTXSID60155545; ZINC3803539

Indication

Disease Entry	ICD 11	Status	REF
Cognitive impairment	6D71	Phase 2	[1]

Cross-matching ID

PubChem CID: 130928
CAS Number: CAS 127390-77-6
TTD Drug ID: DMXLAPF

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
cAMP formation (cAMP form)	TT0QZ8R	NOUNIPROTAC	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Relationship between urinary sodium excretion and pioglitazone-induced edema. J Diabetes Investig. 2010 Oct 19;1(5):208-11.
2	ucb 11056, a new potential nootropic drug, amplifies induced cyclic AMP formation in rat brain tissue. J Neurochem. 1993 Dec;61(6):2256-61.